Scholarlink

Purpose <p>Boron neutron capture therapy (BNCT) dose planning conventionally uses a tumor-to-blood (T/B) ratio derived from the tumor maximum standardized uptake value (SUVmax) of fluorine-18-labeled 4-borono-L-phenylalanine (<sup>1</sup>⁸F-BPA) positron emission tomography (PET) (individual model). It remains unclear whether tumor SUVmax or individual model doses predict outcomes in accelerator-based BNCT for head and neck cancer (HNC). We investigated the correlation of <sup>1</sup>⁸F-BPA PET SUVmax and individual model doses with treatment response.</p> Materials and methods <p>We retrospectively analyzed 30 patients with HNC treated with accelerator-based BNCT (2020–2021). The Kaplan–Meier method was used for survival analysis. Dose parameters (Dmax, Dmin, and D80%) were calculated using the uniform model (T/B = 2.5) and the individual model (T/B = Tumor SUVmax/Blood-pool SUV). Correlations between tumor SUVmax or dose parameters and best treatment response [complete response (CR) vs. non-CR] were evaluated using the Mann–Whitney U test.</p> Results <p>The objective response rate was 90%, and the CR rate was 50%. CR status strongly predicted superior 2&#xa0;years overall survival, locoregional control, and progression-free survival (all <i>p</i> &lt; 0.05). However, no significant differences were observed between the CR and non-CR groups for tumor SUVmax, uniform model doses, or individual model doses (all <i>p</i> &gt; 0.05).</p> Conclusion <p><sup>1</sup>⁸F-BPA PET SUVmax and the conventional individual model did not demonstrate a statistically significant association with CR in patients with HNC after accelerator-based BNCT. These findings question the utility of tumor SUVmax-based dosimetry, suggesting that current models require refinement.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Correlation of tumor maximum standardized uptake value from 18F-BPA PET and boron neutron capture therapy tumor dose with treatment outcomes in head and neck cancer: a retrospective analysis

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年6月2日

查看全文
  • Yuki Yoshino,
  • Satoshi Takeno,
  • Teruhito Aihara,
  • Kayako Isohashi,
  • Naonori Hu,
  • Yasukazu Kanai,
  • Akinori Sasaki,
  • Mai Nojiri,
  • Tetsuya Terada,
  • Shinichi Haginomori,
  • Keiji Nihei,
  • Koji Ono

摘要

Purpose

Boron neutron capture therapy (BNCT) dose planning conventionally uses a tumor-to-blood (T/B) ratio derived from the tumor maximum standardized uptake value (SUVmax) of fluorine-18-labeled 4-borono-L-phenylalanine (1⁸F-BPA) positron emission tomography (PET) (individual model). It remains unclear whether tumor SUVmax or individual model doses predict outcomes in accelerator-based BNCT for head and neck cancer (HNC). We investigated the correlation of 1⁸F-BPA PET SUVmax and individual model doses with treatment response.

Materials and methods

We retrospectively analyzed 30 patients with HNC treated with accelerator-based BNCT (2020–2021). The Kaplan–Meier method was used for survival analysis. Dose parameters (Dmax, Dmin, and D80%) were calculated using the uniform model (T/B = 2.5) and the individual model (T/B = Tumor SUVmax/Blood-pool SUV). Correlations between tumor SUVmax or dose parameters and best treatment response [complete response (CR) vs. non-CR] were evaluated using the Mann–Whitney U test.

Results

The objective response rate was 90%, and the CR rate was 50%. CR status strongly predicted superior 2 years overall survival, locoregional control, and progression-free survival (all p < 0.05). However, no significant differences were observed between the CR and non-CR groups for tumor SUVmax, uniform model doses, or individual model doses (all p > 0.05).

Conclusion

1⁸F-BPA PET SUVmax and the conventional individual model did not demonstrate a statistically significant association with CR in patients with HNC after accelerator-based BNCT. These findings question the utility of tumor SUVmax-based dosimetry, suggesting that current models require refinement.